BioSpace News Archive

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Mammoth Biosciences, Inc., today announced a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types.

Merck, known as MSD outside the United States and Canada, announced financial results for the first quarter of 2024.

Morphic Therapeutic today reported corporate highlights and financial results for the first quarter 2024.

Kymera Therapeutics, Inc. will report first quarter 2024 financial results on May 2, 2024, and will host a conference call at 8:30 a.m. ET.

HOOKIPA Pharma Inc. today announced its final pivotal Phase 2/3 trial design for HB-200 in combination with pembrolizumab. The Phase 2/3 trial design and protocol are based on alignment with the U.S. Food and Drug Administration (FDA) following the Company’s Type C meeting with the FDA.

Nanoscope Therapeutics, Inc. announced today the appointment of Allen C. Ho , MD, FACS, FASRS, as Chief Medical Advisor, where he will help define the strategy of developing the gene mutation-agnostic therapies.

Oncolytics Biotech ® Inc. today announced the acceptance of two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place from May 31 – June 4, 2024.

Ionis Pharmaceuticals, Inc. today published its 2023 Corporate Responsibility Report: Action for a Healthier Future.

Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced that it will share preclinical data that enabled IND clearance for Phase 1/2 testing for its lead RNA exon editing therapy, ACDN-01, in a poster session at the American Society of Gene & Cell Therapy (ASGCT) annual meeting in Baltimore, MD, May 7-11, 2024.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the treatment of retinitis pigmentosa.